MX349879B - Un polimorfismo de un solo nucleotido en el cromosoma 15 que predice las respuestas al tratamiento para el virus de la hepatitis c. - Google Patents

Un polimorfismo de un solo nucleotido en el cromosoma 15 que predice las respuestas al tratamiento para el virus de la hepatitis c.

Info

Publication number
MX349879B
MX349879B MX2014006185A MX2014006185A MX349879B MX 349879 B MX349879 B MX 349879B MX 2014006185 A MX2014006185 A MX 2014006185A MX 2014006185 A MX2014006185 A MX 2014006185A MX 349879 B MX349879 B MX 349879B
Authority
MX
Mexico
Prior art keywords
chromosome
single nucleotide
predicts
nucleotide polymorphism
hcv treatment
Prior art date
Application number
MX2014006185A
Other languages
English (en)
Other versions
MX2014006185A (es
Inventor
Zhu Yonghong
Essioux Laurent
Palermo Giuseppe
Benayed Ryma
T Navarro Mercidita
Riley Gillis Bridget
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014006185A publication Critical patent/MX2014006185A/es
Publication of MX349879B publication Critical patent/MX349879B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a el descubrimiento de las asociaciones que existen entre los polimorfismos de un solo nucleótido (SNP) en el cromosoma 15 y los desenlaces virológicos en una población diversa de pacientes con el virus de la hepatitis C (HCV), que recibieron tratamiento basado en el interferón.
MX2014006185A 2011-11-28 2012-11-26 Un polimorfismo de un solo nucleotido en el cromosoma 15 que predice las respuestas al tratamiento para el virus de la hepatitis c. MX349879B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161564032P 2011-11-28 2011-11-28
PCT/EP2012/073554 WO2013079424A1 (en) 2011-11-28 2012-11-26 A single nucleotide polymorphism on chromosome 15 that predicts hcv treatment responses

Publications (2)

Publication Number Publication Date
MX2014006185A MX2014006185A (es) 2014-07-10
MX349879B true MX349879B (es) 2017-08-16

Family

ID=47221425

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006185A MX349879B (es) 2011-11-28 2012-11-26 Un polimorfismo de un solo nucleotido en el cromosoma 15 que predice las respuestas al tratamiento para el virus de la hepatitis c.

Country Status (11)

Country Link
US (1) US20130137084A1 (es)
EP (1) EP2785875B1 (es)
JP (1) JP5834146B2 (es)
KR (1) KR101656158B1 (es)
CN (1) CN103987862B (es)
BR (1) BR112014012886A2 (es)
CA (1) CA2850904C (es)
ES (1) ES2573500T3 (es)
MX (1) MX349879B (es)
RU (1) RU2606759C2 (es)
WO (1) WO2013079424A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
CN104436197A (zh) 2011-10-21 2015-03-25 艾伯维公司 至少两种直接作用抗病毒剂的组合产品
CN105463084B (zh) * 2015-12-11 2019-04-12 上海新培晶医学检验所有限公司 一种检测白介素28b三个snp位点基因型的试剂盒及其检测方法
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
RU2287825C1 (ru) * 2005-07-25 2006-11-20 Александр Валентинович Ягода СПОСОБ ПРОГНОЗИРОВАНИЯ РЕЗУЛЬТАТОВ ЛЕЧЕНИЯ БОЛЬНЫХ ХРОНИЧЕСКИМ ВИРУСНЫМ ГЕПАТИТОМ С ПРЕПАРАТАМИ ИНТЕРФЕРОНА-α
CN102307589A (zh) 2008-08-28 2012-01-04 沃泰克斯药物股份有限公司 Hcv的基因型分析
CN102257159A (zh) * 2008-12-18 2011-11-23 弗·哈夫曼-拉罗切有限公司 用于hcv治疗应答的生物标志物
RU2012122637A (ru) * 2009-11-14 2013-12-20 Ф.Хоффманн-Ля Рош Аг Биомаркеры для прогнозирования быстрого ответа на лечение гепатита с
CA2795911A1 (en) * 2010-04-13 2011-10-20 F. Hoffmann-La Roche Ag Single nucleotide polymorphisms that predict hcv treatment outcomes
MX2012011805A (es) 2010-04-13 2012-12-17 Hoffmann La Roche Prediccion de respuesta viral precoz en el tratamiento contra hcv.
IT1399564B1 (it) * 2010-04-16 2013-04-19 Metzeler Automotive Profile Guarnizione di tenuta per un autoveicolo, e procedimento per la sua fabbricazione
US20120196272A1 (en) 2010-08-05 2012-08-02 Roche Molecular Systems, Inc. Prediction of HCV Viral Kinetics in Interferon-Free Treatment

Also Published As

Publication number Publication date
EP2785875B1 (en) 2016-04-27
KR20140088168A (ko) 2014-07-09
RU2014124032A (ru) 2016-01-27
CN103987862B (zh) 2016-05-25
HK1200876A1 (en) 2015-08-14
JP5834146B2 (ja) 2015-12-16
CN103987862A (zh) 2014-08-13
MX2014006185A (es) 2014-07-10
BR112014012886A2 (pt) 2017-06-13
RU2606759C2 (ru) 2017-01-10
EP2785875A1 (en) 2014-10-08
WO2013079424A1 (en) 2013-06-06
US20130137084A1 (en) 2013-05-30
CA2850904C (en) 2018-10-02
KR101656158B1 (ko) 2016-09-08
CA2850904A1 (en) 2013-06-06
JP2014533108A (ja) 2014-12-11
ES2573500T3 (es) 2016-06-08

Similar Documents

Publication Publication Date Title
MX349879B (es) Un polimorfismo de un solo nucleotido en el cromosoma 15 que predice las respuestas al tratamiento para el virus de la hepatitis c.
MY183794A (en) Prediction of hcv viral kinetics in interferon-free treatment
MX2012011805A (es) Prediccion de respuesta viral precoz en el tratamiento contra hcv.
PH12015501423A1 (en) Substituted nucleosides, nucleotides and analogs thereof
WO2011106992A8 (en) Inhibitors of hepatitis c virus ns5b polymerase
BR112014008752A2 (pt) polimorfismos de nucleotídeos singulares úteis para predizer a resposta clínica para acetato de glatirâmero
IN2014KN02769A (es)
WO2010025380A3 (en) Analysis of hcv genotypes
MX2013007918A (es) Peptidos inmunogenicos monomericos y multimericos.
MX2016005003A (es) Marcadores geneticos predictivos de respuesta al acetato de glatiramero.
IL258795B (en) Multiallelic genotyping of single nucleotide polymorphisms and indels
ZA201403852B (en) Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection
Stephens Immunogenetic surveillance of HIV/AIDS
PH12014500283A1 (en) Hcv immunotherapy
BR112013024880A2 (pt) seleção de tratamento de hcv
MX2012011804A (es) Polimorfismos de un solo nucleotido que predicen resultados de tratamiento de hcv.
WO2011146788A3 (en) Methods of assessing a risk of developing necrotizing meningoencephalitis
MA35283B1 (fr) Produits de recombinaison destinés à inactiver le gène p0 et leur utilisation
Shchelkanov et al. Genotypic structure of the genus Influenza A virus
PL2215272T3 (pl) Test oporności HCV na leki obejmujący prawie pełny genom
李巧艳 et al. Individuals Having Variant Genotypes of Cytochrome P450 2C19 Is at Increased Risk of Developing Primary Liver Cancer in Han Populations without Infection with Hepatitis Virus
MX2018000213A (es) Metodos para tratar el vhc.
Wang et al. Epidemiological analysis and the prevention policies for the 2010-2013 epidemic of acute viral Hepatitis A in Taiwan
Cao et al. Association between aggressive behaviors and COMT Val158Met and 5-HTTLPR polymorphisms in children
EP2716757A4 (en) MUTANT REPLICON FROM THE GENE OF THE HEPATITIS C VIRUS STRAIN J6CF

Legal Events

Date Code Title Description
FG Grant or registration